Human CD155 / PVR Protein, His Tag (MALS verified)
分子別名(Synonym)
PVR,FLJ25946,PVS,CD155,TAGE4,HVED,NECL5
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human CD155, His Tag (CD5-H5223) is expressed from human 293 cells (HEK293). It contains AA Trp 21 - Asn 343 (Accession # NP_006496.4).
Predicted N-terminus: Trp 21
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 35.9 kDa. The protein migrates as 55-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
CD155是免疫球蛋白超家族中的I型跨膜糖蛋白。CD155通常被稱為脊髓灰質(zhì)炎病毒受體(PVR),因為它參與靈長類動物的細(xì)胞脊髓灰質(zhì)炎病毒感染,CD155的正常細(xì)胞功能是在上皮細(xì)胞之間建立細(xì)胞間粘附連接。CD155/PVR最初是基于其介導(dǎo)脊髓灰質(zhì)炎病毒附著到宿主細(xì)胞的能力而分離的。全長(或CD155α亞型)合成為417個氨基酸(aa)的前體,含有20個aa的信號序列、323個aa的細(xì)胞外區(qū)域、24個aa的TM片段和50個aa的細(xì)胞質(zhì)尾部。胞外區(qū)包含一個N端V型和兩個C2型Ig樣結(jié)構(gòu)域。CD155是一種跨膜蛋白,具有3個細(xì)胞外免疫球蛋白樣結(jié)構(gòu)域D1-D3,其中D1被病毒識別。使用電子顯微鏡獲得了與脊髓灰質(zhì)炎病毒復(fù)合的CD155的低分辨率結(jié)構(gòu),而通過x射線晶體學(xué)解決了CD155的結(jié)構(gòu)域D1和D2的高分辨率結(jié)構(gòu)。
關(guān)鍵字: CD155;CD155蛋白;CD155重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。